BioVectra was acquired by H.I.G. Capital on September 10, 2019

Life Science Company

Out of 60 sectors in the Mergr database, life science ranked 9 in number of deals in 2019. The largest life science acquisition in 2019 was Celgene - which was acquired by Bristol-Myers Squibb for $74.0B.

Join Mergr to view all 230 acquisitions of life science companies in 2019, including 34 acquisitions by private equity firms, and 196 by strategics.

BioVectra, Inc. (BioVectra)

11 Aviation Avenue,
Charlottetown, Prince Edward Island C1E 0A1
Canada,
www.biovectra.com

BioVectra is a supplier of contract manufacturing services to the global pharmaceutical and biotechnology industry and manufactures active pharmaceutical ingredients (API's), chemical intermediates, and bioprocessing reagents.


 Subscribe to unlock this and 161,056
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.1K Private Equity Firms
  • 149K M&A Transactions
  • 157K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.2K M&A Advisors
    (Investment Banks and Law Firms)
  • 47K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.